2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

autologous purged stem cell transplantation and doxorubicin-based chemotherapy
in patients with advanced follicular lymphoma: A randomized multicenter
study by the GOELAMS with final results after a median follow-up of
9 years. Blood. 2009;113:995-1001.
6. Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter
randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional
(CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at
diagnosis: The superior disease control of R-HDS does not translate into an
overall survival advantage. Blood. 2008;111:4004-4013.
7. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy
followed by autologous stem cell transplantation in first remission
prolongs progression-free survival in follicular lymphoma: Results of a prospective,
randomized trial of the German Low-Grade Lymphoma Study
Group. Blood. 2004;104:2667-2674.
8. Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with
interferon compared with CHOP followed by high-dose therapy with autologous
stem cell transplantation in untreated patients with advanced follicular
lymphoma: The GELF-94 randomized study from the Groupe d’Etude des
Lymphomes de l’Adulte (GELA). Blood. 2006;108:2540-2544.
9. Rohatiner AZ, Nadler L, Davies AJ, et al. Myeloablative therapy with
autologous bone marrow transplantation for follicular lymphoma at the time
of second or subsequent remission: Long-term follow-up. J Clin Oncol.
2007;25:2554-2559.
10. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves
progression-free survival and survival in relapsed follicular non-Hodgkin’s
lymphoma: Results from the randomized European CUP trial. J Clin Oncol.
2003;21:3918-3927.
11. Zelentz AD, Abramson JA, Advani RA, et al. NCCN Clinical Practice
Guidelines in Oncology: Non-Hodgkin’s Lymphomas. http://www.nccn.org/
professionals/physician_gls/f_guidelines.asp. Accessed January 11, 2012.
12. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment
recommendations from the Fourth International Workshop on Waldenstrom’s
Macroglobulinemia. J Clin Oncol. 2009;27:120-126.
13. van Besien K, Loberiza FR, Jr., Bajorunaite R, et al. Comparison of
autologous and allogeneic hematopoietic stem cell transplantation for follicular
lymphoma. Blood. 2003;102:3521-3529.
14. Ingram W, Devereux S, Das-Gupta EP, et al. Outcome of BEAMautologous
and BEAM-alemtuzumab allogeneic transplantation in relapsed
advanced stage follicular lymphoma. Br J Haematol. 2008;141:235-243.
15. Evens AM, Vanderplas A, LaCasce AS, et al. Outcomes with autologous
(auto) and allogeneic (allo) stem cell transplantation (SCT) for relapsed/
refractory follicular lymphoma (FL) in the post-rituximab era: A comparative
analysis from the National Comprehensive Cancer Network (NCCN) Non-
Hodgkin’s Lymphoma (NHL) Outcomes Database Project. Blood. 2011;118
(abstr 4112).
16. Tomblyn MR, Ewell M, Bredeson C, et al. Autologous versus reducedintensity
allogeneic hematopoietic cell transplantation for patients with
chemosensitive follicular non-Hodgkin lymphoma beyond first complete response
or first partial response. Biol Blood Marrow Transplant. 2011;17:
1051-1057.
17. Hari P, Carreras J, Zhang MJ, et al. Allogeneic transplants in follicular
lymphoma: Higher risk of disease progression after reduced-intensity compared
to myeloablative conditioning. Biol Blood Marrow Transplant. 2008;
14:236-245.
18. Sorror ML, Storer BE, Maloney DG, et al. Outcomes after allogeneic
500
CASSADAY AND GOPAL
hematopoietic cell transplantation with nonmyeloablative or myeloablative
conditioning regimens for treatment of lymphoma and chronic lymphocytic
leukemia. Blood. 2008;111:446-452.
19. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation
(HCT)-specific comorbidity index: A new tool for risk assessment before
allogeneic HCT. Blood. 2005;106:2912-2919.
20. Avivi I, Montoto S, Canals C, et al. Matched unrelated donor stem cell
transplant in 131 patients with follicular lymphoma: An analysis from the
Lymphoma Working Party of the European Group for Blood and Marrow
Transplantation. Br J Haematol. 2009;147:719-728.
21. Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with
allogeneic stem cell transplantation for relapsed follicular lymphoma after
nonmyeloablative conditioning with fludarabine, cyclophosphamide, and
rituximab. Blood. 2008;111:5530-5536.
22. Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative allogeneic
hematopoietic cell transplantation in relapsed, refractory, and transformed
indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:211-217.
23. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumabcontaining
reduced-intensity allogeneic transplantation regimen for relapsed
and refractory non-Hodgkin lymphoma. Blood. 2004;104:3865-3871.
24. Pinana JL, Martino R, Gayoso J, et al. Reduced intensity conditioning
HLA identical sibling donor allogeneic stem cell transplantation for patients
with follicular lymphoma: Long-term follow-up from two prospective multicenter
trials. Haematologica. 2010;95:1176-1182.
25. Shea T, Johnson J, Westervelt P, et al. Reduced-intensity allogeneic
transplantation provides high event-free and overall survival in patients with
advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow
Transplant. 2011;17:1395-1403.
26. Thomson KJ, Morris EC, Milligan D, et al. T-cell-depleted reducedintensity
transplantation followed by donor leukocyte infusions to promote
graft-versus-lymphoma activity results in excellent long-term survival in
patients with multiply relapsed follicular lymphoma. J Clin Oncol. 2010;28:
3695-3700.
27. Khouri IF, Saliba RM, Valverde R, et al. Nonmyeloablative allogeneic
stem cell transplantation with or without 90-yttrium ibritumomab tiuxetan
(90YIT) is curative for relapsed follicular lymphoma: Median 9-year follow-up
results. Blood. 2011;118 (abstr 662).
28. Bethge WA, Lange T, Meisner C, et al. Radioimmunotherapy with
yttrium-90-ibritumomab tiuxetan as part of a reduced-intensity conditioning
regimen for allogeneic hematopoietic cell transplantation in patients with
advanced non-Hodgkin lymphoma: Results of a phase 2 study. Blood. 2010;
116:1795-1802.
29. Gopal AK, Guthrie KA, Rajendran J, et al. Y-Ibritumomab tiuxetan,
fludarabine, and TBI-based nonmyeloablative allogeneic transplantation
conditioning for patients with persistent high-risk B-cell lymphoma. Blood.
2011;118:1132-1139.
30. Ram R, Gooley TA, Maloney DG, et al. Histology and time to progression
predict survival for lymphoma recurring after reduced-intensity conditioning
and allogeneic hematopoietic cell transplantation. Biol Blood Marrow
Transplant. 2011;17:1537-1545.
31. Eide MB, Lauritzsen GF, Kvalheim G, et al. High-dose chemotherapy
with autologous stem cell support for patients with histologically transformed
B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study.
Br J Haematol. 2011;152:600-610.